<i>BRAF</i> mutation is not associated with an increased risk of recurrence in patients undergoing resection of colorectal liver metastases
Stéphane Benoist(Bicêtre Hospital), Benoı̂t Rousseau(Memorial Sloan Kettering Cancer Center), Luca Viganò(Humanitas University), Guillaume Passot(Université Claude Bernard Lyon 1), Antoine Brouquet(Bicêtre Hospital), Maximiliano Gelli(Université Paris-Saclay), Pascal Artru(Université Paris Cité), Lilian Schwarz(Université de Rouen Normandie), Vincent Hautefeuille(Centre Hospitalier Universitaire Amiens-Picardie), Tchalla Ameto(Hôpital Claude Huriez), Loïc Raoux(Université Toulouse III - Paul Sabatier), Ugo Marchèse(Institut Paoli-Calmettes), Christelle de la Fouchardière(Aix-Marseille Université), Jean‐Yves Mabrut(Hôpital Beaujon), Céline Lepère(Assistance Publique – Hôpitaux de Paris), Stéphanie Truant, Bertrand Le Roy(Centre Hospitalier Universitaire de Saint-Étienne), António Sá Cunha(Assistance Publique – Hôpitaux de Paris), Nathan Moreno-Lopez(Maison des Sciences sociales et des Humanités de Dijon), Alexis Laurent(Université Paris-Est Créteil), Romain Coriat(Hôpital Cochin), Astrid Herrero(Hôpital Saint Eloi), Sophie Deguelte Lardiere(Centre Hospitalier Universitaire de Reims)
Cited by 42
Related Papers
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
|New England Journal of Medicine|2018|2.8k
Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial
|The Lancet Oncology|2021|1.3k
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
|Journal of Clinical Oncology|2020|1.2k
Combination Chemotherapy in Advanced Adrenocortical Carcinoma
|New England Journal of Medicine|2012|863
Efficacy of Selpercatinib in <i>RET</i> -Altered Thyroid Cancers
|New England Journal of Medicine|2020|766